BR112021019003A2 - Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer - Google Patents
Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncerInfo
- Publication number
- BR112021019003A2 BR112021019003A2 BR112021019003A BR112021019003A BR112021019003A2 BR 112021019003 A2 BR112021019003 A2 BR 112021019003A2 BR 112021019003 A BR112021019003 A BR 112021019003A BR 112021019003 A BR112021019003 A BR 112021019003A BR 112021019003 A2 BR112021019003 A2 BR 112021019003A2
- Authority
- BR
- Brazil
- Prior art keywords
- nanoparticles
- poly
- alkyl cyanoacrylate
- cancer treatment
- cyanoacrylate
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer. é aqui descrito uma droga anticâncer hidrofóbica encapsulada em nanopartículas de poli (alquil cianoacrilato) e seu uso em tratamentos de câncer por rota de administração intracavitária, tal como administração intraperitoneal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20180429 | 2018-03-27 | ||
US16/366,596 US11806330B2 (en) | 2018-03-27 | 2019-03-27 | PACA and cabazitaxel for anti-cancer treatment |
PCT/EP2019/076121 WO2020192950A1 (en) | 2018-03-27 | 2019-09-26 | Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021019003A2 true BR112021019003A2 (pt) | 2021-11-30 |
Family
ID=66049182
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112020019452-2A BR112020019452A2 (pt) | 2018-03-27 | 2019-03-27 | Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer |
BR112021019003A BR112021019003A2 (pt) | 2018-03-27 | 2019-09-26 | Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112020019452-2A BR112020019452A2 (pt) | 2018-03-27 | 2019-03-27 | Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer |
Country Status (8)
Country | Link |
---|---|
US (3) | US20210113482A1 (pt) |
EP (2) | EP3773471A1 (pt) |
JP (2) | JP7317038B2 (pt) |
CN (2) | CN111989087A (pt) |
AU (1) | AU2019437385A1 (pt) |
BR (2) | BR112020019452A2 (pt) |
CA (1) | CA3134923A1 (pt) |
WO (2) | WO2019185685A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020019452A2 (pt) * | 2018-03-27 | 2021-01-05 | Sintef Tto As | Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer |
US11957793B2 (en) * | 2018-08-23 | 2024-04-16 | Sintef Tto As | Nanoparticles |
IL295800A (en) * | 2020-02-26 | 2022-10-01 | Biosergen As | Therapeutic polyene macrolide pharmaceutical preparations and methods of using them |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2872703B1 (fr) * | 2004-07-07 | 2006-10-06 | Ethypharm Sa | Nanoparticules polymeriques composites |
US20090117177A1 (en) | 2005-05-23 | 2009-05-07 | Natalia Rapoport | Echogenic microbubbles and microemulsions for ultrasound-enhanced nanoparticle-mediated delivery of agents |
EP1876188A1 (en) | 2006-07-04 | 2008-01-09 | NanoDel Technologies GmbH | Two step miniemulsion process |
US8679539B2 (en) * | 2007-01-31 | 2014-03-25 | Tong Shen Enterprise Co., Ltd. | Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof |
FR2921660B1 (fr) | 2007-10-01 | 2015-09-25 | Centre Nat Rech Scient | Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer. |
EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
EP2508207B1 (en) * | 2011-03-31 | 2013-05-08 | BioAlliance Pharma | Nanoparticles loaded with chemotherapeutic antitumoral Drug |
WO2014065513A1 (ko) | 2012-10-25 | 2014-05-01 | 서강대학교 산학협력단 | 약물을 함유한 나노입자가 결합된 초음파 조영제 및 이의 제조방법 |
US10967039B2 (en) * | 2013-05-28 | 2021-04-06 | Sintef Tto As | Process for preparing stealth nanoparticles |
US10391185B2 (en) | 2014-11-26 | 2019-08-27 | Fujifilm Visualsonics, Inc. | Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles |
WO2016134115A1 (en) | 2015-02-20 | 2016-08-25 | Trustees Of Boston University | Theranostic compositions and uses thereof |
US10925852B2 (en) * | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
WO2017078099A1 (ja) * | 2015-11-06 | 2017-05-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
ES2861449T3 (es) * | 2015-12-02 | 2021-10-06 | Stcube & Co Inc | Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos |
WO2017143967A1 (zh) | 2016-02-24 | 2017-08-31 | 首都医科大学宣武医院 | 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途 |
KR20170133257A (ko) | 2016-05-24 | 2017-12-05 | 한양대학교 산학협력단 | 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물 |
NO342271B1 (en) * | 2016-09-29 | 2018-04-30 | Sintef Tto As | A new drug delivery system for treatment of cancer |
WO2018060437A1 (en) * | 2016-09-29 | 2018-04-05 | Sintef Tto | A new drug delivery system for treatment of disease |
BR112020019452A2 (pt) | 2018-03-27 | 2021-01-05 | Sintef Tto As | Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer |
US20220257525A1 (en) | 2019-03-27 | 2022-08-18 | Sintef Tto As | Drug delivery system for treatment of cancer |
-
2019
- 2019-03-27 BR BR112020019452-2A patent/BR112020019452A2/pt unknown
- 2019-03-27 US US17/041,094 patent/US20210113482A1/en active Pending
- 2019-03-27 WO PCT/EP2019/057678 patent/WO2019185685A1/en active Application Filing
- 2019-03-27 EP EP19715854.6A patent/EP3773471A1/en active Pending
- 2019-03-27 JP JP2020552260A patent/JP7317038B2/ja active Active
- 2019-03-27 CN CN201980022079.9A patent/CN111989087A/zh active Pending
- 2019-03-27 US US16/366,596 patent/US11806330B2/en active Active
- 2019-09-26 CA CA3134923A patent/CA3134923A1/en active Pending
- 2019-09-26 AU AU2019437385A patent/AU2019437385A1/en active Pending
- 2019-09-26 EP EP19779462.1A patent/EP3946253A1/en active Pending
- 2019-09-26 WO PCT/EP2019/076121 patent/WO2020192950A1/en unknown
- 2019-09-26 JP JP2021560300A patent/JP2022527858A/ja active Pending
- 2019-09-26 BR BR112021019003A patent/BR112021019003A2/pt not_active Application Discontinuation
- 2019-09-26 CN CN201980096306.2A patent/CN113840594A/zh active Pending
- 2019-11-12 US US16/583,687 patent/US20200061019A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3946253A1 (en) | 2022-02-09 |
CN111989087A (zh) | 2020-11-24 |
CA3134923A1 (en) | 2020-10-01 |
JP7317038B2 (ja) | 2023-07-28 |
US11806330B2 (en) | 2023-11-07 |
BR112020019452A2 (pt) | 2021-01-05 |
WO2019185685A1 (en) | 2019-10-03 |
AU2019437385A1 (en) | 2021-11-04 |
JP2021519323A (ja) | 2021-08-10 |
US20200061019A1 (en) | 2020-02-27 |
CN113840594A (zh) | 2021-12-24 |
US20190298682A1 (en) | 2019-10-03 |
JP2022527858A (ja) | 2022-06-06 |
US20210113482A1 (en) | 2021-04-22 |
EP3773471A1 (en) | 2021-02-17 |
WO2020192950A1 (en) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021019003A2 (pt) | Nanopartículas de poli (alquil cianoacrilato) para uso em tratamento de câncer | |
CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
CL2017003458A1 (es) | Metodos para tratar malignidad hematoligica usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
CO2017007662A2 (es) | Terapias de combinación para el tratamiento de cánceres | |
CL2017003457A1 (es) | Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
BR112018010418A8 (pt) | complexo de agente quimioterápico em microbolhas para terapia sonodinâmica | |
AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
NZ745556A (en) | Androgen receptor modulator and uses thereof | |
AR096402A1 (es) | Medicamento de metformina y dihidroquercetina | |
ECSP11011552A (es) | Administracion continua de cilengitida en tratamientos contra el cancer | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
PH12018501451A1 (en) | Formulations for treating bladder cancer | |
UY36202A (es) | Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer | |
BR112017009845A2 (pt) | dianidrogalactitol juntamente com radiação para tratar carcinoma de célula não pequena dos pulmões e glioblastoma multiforme | |
CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
MX2022003190A (es) | Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. | |
NZ734750A (en) | Cancer therapy with a parvovirus combined with bevacizumab | |
CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
PH12018500450A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
ZA201908446B (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof | |
MX2018008196A (es) | Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional. | |
BR112018011203A2 (pt) | terapia de combinação para câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |